We are a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. Our lead AMPK activator compound O304 is currently in Phase IIa clinical trial. This homepage is currently under revision and will be updated soon!

News room
Selected Slides